The “Neoantigen Targeted Therapies Market, 2019-2030” report features a comprehensive study from the curr
To buy this detailed 320 page report, check out here
• A detailed assessment of the present market landscape, supplying info on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, kind of molecule (small molecule and biologic), kind of treatment (personalized and off-the-shelf), kind of therapy (monotherapy and combination therapy), kind of immunotherapy, target indication, type of treatment, and route of administration from the drugs / therapies which are being developed to treat cancer.
• Detailed profiles of developers of neoantigen targeted therapies (shortlisted based on the amount of pipeline products), featuring an introduction to the organization, its financial information (if available), an in depth description of their product portfolio and up to date collaborations. Additionally, each profile includes an educated future outlook.
• A detailed publication analysis of near to 300 peer-reviewed, scientific articles printed throughout the period 2015-2019 (till Feb), highlighting the study focus inside the industry. Additionally, it highlights the important thing trends observed over the publications, including information on the right track disease indications, affiliated cancer immunotherapies, and analysis according to various relevant parameters, for example study type (review article, research article and meta-analysis), year of publication, and many popular journals (when it comes to quantity of articles printed within the with time period) in this particular domain.
• An in-depth research into the various patents which have been filed / granted associated with neoantigens till April 2019. It offers info on key parameters, for example patent type, publication year, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (when it comes to size ip portfolio).
• An research into the various partnerships relating to neoantigen targeting therapies, that have been established till March 2019, according to various parameters, like the kind of partnership, year of partnership, target disease indications, kind of immunotherapy and also the most active players.
• An research into the investments made, including seed financing, investment capital financing, debt financing, grants, capital elevated from IPOs and subsequent choices, at various stages of rise in firms that are centered on developing neoantigen targeted therapies.
• Informed estimates from the existing market size and also the future chance for neoantigen targeted therapies, within the next decade. According to multiple parameters, for example disease prevalence, anticipated adoption of neoantigen targeted therapies and also the likely selling cost of these therapeutic products, we’ve provided informed estimates around the evolution of the marketplace for the time 2019-2030.
The report also features the likely distribution of the present and forecasted chance across important areas, pointed out below:
• Type of target disease indication
• Bone cancer
• Colorectal cancer
• Gynecological cancer
• Non-small cell cancer of the lung
• Renal cell carcinoma
• Other cancers
• Type of neoantigens
• Personalized neoantigens
• Off-the-shelf neoantigens
• Type of immunotherapy
• Dendritic cell vaccines
Pr Release: Variation 4 (Format 5)
• DNA / RNA-based vaccines
• Protein / peptide-based vaccines
• TIL-based therapies
• Route of administration
• Other routes
• Key geographical regions
• North America
• Rest around the globe
The report also features inputs from eminent industry stakeholders, based on whom neoantigen targeted therapies are anticipated is the newest part of cancer immunotherapy. Much like Vehicle-T cell therapies, these therapies have, to date, shown significant therapeutic potential and promising clinical outcomes. The report includes detailed transcripts of discussions held using the following experts:
• Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)
• Ella Sorani (V . P . Development and research, BioLineRx)
• Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)
To request sample pages, check out here
Key Questions Clarified
• What would be the prevalent trends associated with R&D activity centered on neoantigen based therapies?
• What would be the clinical conditions that neoantigen targeted therapies are now being developed?
• What would be the key challenges faced by neoantigen-based therapy developed?
• Who would be the leading industry and non-industry players?
• What would be the important aspects that will probably influence the evolution from the neoantigen targeted therapies market?
• What would be the causes of partnership activity among stakeholders within this industry?
• Who would be the key investors in neoantigen targeted therapies?
• What is share of neoantigen targeted therapies within the immunotherapy market?
• How may be the current and future market chance apt to be distributed across key areas and geographies?
Leave a Reply